InspireMD (NYSE:NSPR) Trading Down 0.2% – Should You Sell?

InspireMD, Inc. (NYSE:NSPR) dropped 0.2% during trading on Tuesday . The company traded as low as $0.71 and last traded at $0.7175. Approximately 15,164 shares traded hands during mid-day trading, a decline of 91% from the average session volume of 170,852 shares. The stock had previously closed at $0.7190.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on NSPR. Lake Street Capital set a $4.00 target price on InspireMD in a report on Monday, May 4th. Piper Sandler reissued an “overweight” rating and issued a $3.00 target price (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $4.50.

InspireMD Stock Down 0.2%

The company’s fifty day moving average price is $0.86 and its 200 day moving average price is $1.36. The company has a market capitalization of $33.61 million, a P/E ratio of -0.96 and a beta of 0.78.

Insider Buying and Selling

In related news, CEO Marvin Slosman purchased 21,000 shares of InspireMD stock in a transaction that occurred on Tuesday, May 12th. The shares were acquired at an average price of $1.20 per share, with a total value of $25,200.00. Following the completion of the transaction, the chief executive officer directly owned 3,556,658 shares of the company’s stock, valued at $4,267,989.60. This represents a 0.59% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Paul Stuka acquired 65,626 shares of the stock in a transaction on Friday, May 8th. The shares were bought at an average price of $1.16 per share, for a total transaction of $76,126.16. Following the purchase, the director owned 622,871 shares in the company, valued at approximately $722,530.36. This trade represents a 11.78% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders acquired 303,771 shares of company stock worth $348,697. 34.06% of the stock is owned by corporate insiders.

Institutional Trading of InspireMD

Several large investors have recently modified their holdings of the stock. Aberdeen Group plc lifted its position in InspireMD by 27.9% during the fourth quarter. Aberdeen Group plc now owns 3,173,364 shares of the company’s stock worth $5,649,000 after purchasing an additional 692,247 shares during the period. Ingalls & Snyder LLC grew its stake in InspireMD by 70.8% during the fourth quarter. Ingalls & Snyder LLC now owns 384,300 shares of the company’s stock worth $684,000 after buying an additional 159,298 shares in the last quarter. Velan Capital Investment Management LP increased its holdings in InspireMD by 137.1% in the 3rd quarter. Velan Capital Investment Management LP now owns 2,143,698 shares of the company’s stock valued at $5,166,000 after buying an additional 1,239,669 shares during the period. Millennium Management LLC increased its holdings in InspireMD by 766.3% in the 3rd quarter. Millennium Management LLC now owns 147,423 shares of the company’s stock valued at $355,000 after buying an additional 130,405 shares during the period. Finally, Citadel Advisors LLC raised its position in shares of InspireMD by 45.0% in the 3rd quarter. Citadel Advisors LLC now owns 37,954 shares of the company’s stock valued at $91,000 after buying an additional 11,778 shares in the last quarter. 44.78% of the stock is owned by institutional investors and hedge funds.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.